COOPER COMPANIES INC
CIK 711404 · Ver em SEC EDGAR ↗
Primeira declaração à SEC: 3 de Novembro de 2004 · Último: 3 de Novembro de 2004
Nesta página
- Biografia Histórico de carreira e perfil público, quando disponível.
- Investidor com informação privilegiada em Empresas onde esta pessoa é um insider reporting.
- Transações de insiders Todas as ações que esta pessoa comprou ou vendeu, a partir dos registros do Formulário 4.
- Derivativos Opções e outras participações em derivativos reportadas por esta pessoa.
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.
Ler mais
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.
History
Parker Montgomery, a lawyer, bought Martin H. Smith Co. in 1958. The company was renamed to Cooper, Tinsley Laboratories, Inc. in 1961. Its name was changed to Cooper Laboratories Inc. in 1967, and entered the contact lens business when it acquired British lens maker GlobalVision in 1972.
In 1980, Cooper Laboratories reorganized into three business groups: CooperVision, CooperCare and CooperBiomedical, with Cooper Medical Devices Corp. added as a fourth group one year later.
The company was renamed The Cooper Companies in 1987. Three years later, it was further restructured into three business units: CooperVision, CooperSurgical and CooperVision Pharmaceuticals (dissolved in 2003).
Currently, the firm operates as two business units: CooperVision and CooperSurgical. CooperVision serves contact lens wearers and eye care practitioners. Products include a range of daily, two-week and monthly disposable contact lenses, and other spherical, toric and multifocal lenses for astigmatism, nearsightedness and farsightedness, and presbyopia.
CooperSurgical is the medical device and fertility and genomics unit of the companies. It became a business unit in 1990 and its focus includes women's health and fertility. It is headquartered in Trumbull, Connecticut.
Acquisitions
Ocular Sciences Inc. was acquired by CooperVision in 2005.
CooperSurgical acquired AEGEA Medical, a medical manufacturing company in February 2021. A month later, in March, the company acquired Safe Obstetric Systems, and in December 2021, CooperSurgical acquired Generate Life Sciences for $1.6 billion.
In March 2022, CooperSurgical acquired Cook Medical's reproductive health business for $875 million. During that same year the company acquired EnsEyers, a supplier of orthokeratology and scleral contact lenses.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
Investidor com informação privilegiada em
Transações de insiders
Variação de preço vs cotação atual, ajustada por desdobramentos para ações corporativas desde o arquivamento — não comparada a benchmark, não anualizada, não ponderada por tamanho
Nenhuma negociação em mercado aberto registrada; exibindo todos os arquivamentos.
| Data | Ticker | Código | Ações | Preço | Valor | Detido após | Δ próprio | A/D | vs agora |
|---|---|---|---|---|---|---|---|---|---|
| 1 de Novembro de 2004 | COO | A | 18.900 | $69,39 | $1.311.471 | 18.900 Direto | — | Adquirido | 336,8% (preço em 2026-08-21) |
P = Compra em mercado aberto · S = Venda · A = Concessão/prêmio · M = Exercício de opção · G = Presente · F = Retenção de impostos
Transações de insiders não são uma recomendação; vendas são frequentemente motivadas por liquidez ou razões fiscais.
Participações em derivativos (Formulário 4 Tabela II)
Opções, RSUs e títulos conversíveis reportados no Formulário 4 Tabela II.
| Data | Ticker | Título | Subjacente | Preço de exercício | Expiração | Ações | A/D |
|---|---|---|---|---|---|---|---|
| 1 de Novembro de 2004 | COO | Common Stock | Common Stock (18.900) | $69,39 | 1 de Novembro de 2014 | 18.900 | Adquirido |
O preço de exercício/conversão fica em branco quando não aplicável (por exemplo, RSUs).